Conference Call with Krsnaa Diagnostics Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.
Conference Call with Krsnaa Diagnostics Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Krsnaa Diagnostics announced Q1FY24 results: Total Income of Rs 1,438 million in Q1FY24 compared to Rs 1,175 million in Q1FY23, up 22% YoY EBITDA of Rs 319 million in Q1FY24 compared to Rs 283 million in Q1FY23, up 13% YoY EBITDA Margin of 23% in Q1FY24 compared to 25% in Q1FY23 Profit After Tax of Rs 146 million in Q1FY24 compared to Rs 142 million in Q1FY23, up 3% YoY Reported Diluted EPS of Rs 4.52 in Q1FY24 compared to Rs 4.51 in Q1FY23 Net Cash position of Rs 2,246 million Receivable days decline from 86 days in Q1FY23 to 79 days in Q1FY24 Krsnaa won the tender in Assam for the establishment of 10 laboratories and 1,256 collection centres spanning all districts in Assam. Krsnaa expanded its presence by establishing 97 new centres across the nation. Commenting on the Business, Pallavi Bhatevara, Managing Director, said, “Addressing the initial challenges encountered in the new fiscal year, I am pleased to share a positive turn of events. The esteemed High Court of Rajasthan has ruled in favor of Krsnaa Diagnostics and TCIL, directing both entities to meet the stipulated conditions regarding additional performance security. In line with this judgment, the Authorities are also willing to go ahead with the Agreement and execute the project and no contest remains between the parties. Furthermore, I am delighted to announce we have recently executed an agreement for the Assam pathology tender, a significant opportunity encompassing 10 Labs and 1,256 collection centres. This strengthens our widespread presence across all districts of Assam. Presently, Krsnaa Diagnostics is poised to deploy 51 CT scan units, and 2 MRI machines, establish 168 labs, and set up 3,705 collection centres, all under various contractual agreements. These recent contract wins underscore the exceptional capabilities of our in-house teams, reflecting their adeptness in navigating the intricate bidding process, meeting prerequisites, and ultimately securing these contracts. As we embark on these projects, Krsnaa Diagnostics continues to expand its footprint into new geographical regions, establishing a robust foundation for sustainable, long-term growth.” Result PDF
Conference Call with Krsnaa Diagnostics Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Krsnaa Diagnostics announced FY23 results: Revenue from Operations registered a Revenue of Rs 4,871 million, an increase of 7.0% on a YoY basis EBITDA of Rs 1,240 million, with Margins of 25.4% Profit After Tax of Rs 621 million, with margins of 12.8% Core business of Radiology and Pathology registered a Revenue of Rs 4,864 million, an increase of 14.8% on a YoY basis and Covid-19 Revenues decreased by 97.8% to Rs 7 million Cash Generated from Operating Activities Before Tax of Rs 89 crore Net Cash position of Rs 272 crore as of 31st March 2023 The Board of Directors has recommended a dividend of Rs 2.75 per share, 55% of the Face Value Commenting on the Business, Pallavi Bhatevara, Managing Director, said: “Krsnaa Diagnostics has firmly established itself as the leading provider of premium quality integrated diagnostic services in India, with a robust network spanning over 2,850 locations. Our primary focus remains on addressing the healthcare needs of our society by ensuring accessibility and affordability of our services. As part of our growth strategy, we successfully operationalized 26 radiology centers, 50 pathology labs, and 556 collection centers during FY2023, further expanding our reach and service offerings. We are immensely proud to share that our Teleradiology hub in Pune has achieved accreditation from the prestigious NABH. This recognition is a significant milestone in the history of Indian healthcare, making our teleradiology hub the 1 st to receive such esteemed accreditation from NABH. This accreditation serves as a testament to our unwavering commitment to delivering high-quality healthcare services by embracing cutting-edge technologies. Furthermore, we have achieved notable success in last twelve months by securing nine tenders across various states. All these projects encompass 53 CT and MRI centres,158 Pathology labs, and 2,281 Pathology collection centers substantially strengthening our growth prospects for the future. Looking ahead, we are excited about the upcoming operationalization of these projects, as they present substantial growth opportunities for us. These projects will enable us to strengthen our presence, reach more customers, and create new growth paths in these regions. We remain dedicated to delivering exceptional services and maximizing our impact as we continue to expand our footprint across the country.” Result PDF